5-MeO-DMT vs DMT: two related molecules with very different research records

THE SHORT VERSION · SWIPE

▶ Watch it as a 20-second video

‹›

5-MeO-DMT and DMT (N,N-DMT, often written NN-DMT) share most of their name and most of their structure, so they are often lumped together. The research literature treats them as two different drugs. They differ in the receptors they favour, in what people report, in where they occur in nature, and in how far they have gone in clinical trials. For DMT on its own, start with what is DMT.

This guide compares the two side by side, using published studies and Canadian legal texts. It does not describe how to obtain, prepare or use either substance, and it gives no amounts.

How do 5-MeO-DMT and DMT compare at a glance?

Durations in the table come from different routes and settings, so they are not a like-for-like comparison. Sources for each row are given in the sections below.

What is the chemical difference between 5-MeO-DMT and DMT?

Both are tryptamines, built on the same indole skeleton as serotonin. The Canadian schedule describes DMT as 3-[(2-dimethylamino)ethyl]indole (Justice Laws, CDSA, Schedule III). 5-MeO-DMT, short for 5-methoxy-N,N-dimethyltryptamine, is the same molecule with a methoxy group (an oxygen bonded to a methyl group) attached at position 5 of the ring. Evidence: established. Our DMT chemical structure guide shows both molecules part by part.

That one group matters for how the body handles the drug. 5-MeO-DMT is broken down mainly by the enzyme monoamine oxidase A (MAO-A). A second enzyme, CYP2D6, removes the methyl from the methoxy group and turns it into bufotenine, an active metabolite (Reckweg et al., 2022). DMT is also broken down mainly by MAO-A (Barker, 2018). Both are fast-acting and short-lived, partly for this reason. Evidence: established.

How do their receptor profiles differ?

Most classic psychedelics, DMT included, produce their main effects by activating the 5-HT2A receptor. A 2018 review of DMT says its subjective effects appear to act primarily through 5-HT2A, and it cites a mouse study in which DMT’s signature head-twitch response disappeared in animals bred without that receptor. The same review notes that DMT binds many other serotonin receptors as well, including 5-HT1A, and that 5-HT2A is not the whole explanation (Barker, 2018). Evidence: established.

5-MeO-DMT leans the other way. A 2022 review summarising two binding studies on human cloned receptors reports that it binds most strongly to the 5-HT1A receptor, with 300 to 1,000-fold selectivity over 5-HT2A (Reckweg et al., 2022). Evidence: established in binding studies.

It still acts at 5-HT2A: in animals, its head-twitch response is blocked only by drugs that block 5-HT2A. But several of its other effects in rodents are reduced by a 5-HT1A blocker and not by a 5-HT2A blocker. The review adds that 5-HT1A activation tends to lower heart rate and blood pressure, while 5-HT2A activation tends to raise them (Reckweg et al., 2022). Evidence: preliminary, from animal work.

Researchers suspect this 5-HT1A tilt helps explain why 5-MeO-DMT feels different. An observational study at two ceremonies says it induces comparatively less visual imagery, which “may relate to its unusually high agonism” at 5-HT1A (Timmermann et al., 2025). That is a hypothesis, not a demonstrated mechanism in people. Evidence: preliminary.

Where are 5-MeO-DMT and DMT found in nature?

DMT is widespread. Its natural occurrence in plants was reported in 1946, and it has been found in mammalian tissue as well; it was first synthesized in 1931 by the Canadian chemist Richard Manske (Barker, 2018). Whether the human body makes 5-MeO-DMT is a different question: the same review says further studies are needed to determine whether it actually exists in humans. Evidence: established for DMT; unresolved for 5-MeO-DMT in humans.

5-MeO-DMT has a narrower known range. A 2022 review reports small amounts in a few plants that typically contain DMT too, and says indigenous ceremonial use of 5-MeO-DMT has been suggested but strong evidence is lacking (Reckweg et al., 2022). We deliberately do not list the plants. Evidence: established.

It is best known from an animal. The Sonoran Desert toad, Incilius alvarius, is described as the only animal known to secrete 5-MeO-DMT as a chemical defence. A 2025 field study in Arizona found it in every Sonoran Desert toad sampled and not in the other toads living alongside them. Diet did not explain it, and how the toad comes to have the compound is still unknown (Luccioni et al., 2025). Evidence: preliminary, from one field study.

The toad’s secretion is not just 5-MeO-DMT: it also contains bufotenine and other active substances, including compounds that act on the heart (Reckweg et al., 2022). Evidence: established.

Is the Sonoran Desert toad at risk?

Researchers have raised the concern. The 2022 review notes that the toad is not listed as endangered on the IUCN Red List, but that this classification rests on an assessment from 2004. Its authors argue that rising demand for the secretion could harm the species through habitat invasion, excessive handling of toads, amphibian trafficking and black-market dynamics, and they say a switch to synthetic 5-MeO-DMT would avoid this. They also argue the secretion is too complex and variable a mixture to develop as a medicine (Reckweg et al., 2022). Evidence: preliminary; this is the authors’ argument.

Field researchers act on the same worry. The 2025 field study, carried out under Arizona collecting licenses and with the toads released after sampling, published its site locations only approximately “due to conservation concerns” (Luccioni et al., 2025). What we could not find is a recent population assessment, so how much pressure the species is actually under is unresolved. Evidence: unresolved.

How do the reported effects differ in research?

The clearest contrast is visual. In a placebo-controlled lab study of intravenous DMT in 13 healthy volunteers, the authors describe its effects as marked by “unusually vivid visual imagery” and body sensations arising within seconds (Timmermann et al., 2019). Evidence: established. For the DMT side in depth, see what does DMT feel like.

By contrast, a review of 5-MeO-DMT describes its core effect as ego dissolution, a sense of oneness or of loosened boundaries between self and world, “in the absence of visual imagery”. The same review states the contrast directly: DMT is known for vivid, complex imagery rather than marked ego dissolution (Reckweg et al., 2022). A second review lists the “relative lack of visual effects” and possibly higher rates of ego dissolution and mystical experiences among 5-MeO-DMT’s distinguishing features (Ermakova et al., 2022). Evidence: preliminary, from reviews of mostly survey data.

The picture is not absolute. The 2025 ceremony study, with 14 participants interviewed in detail, found the 5-MeO-DMT experience moved through phases. Some people described shapes, colours or “shattering visuals” at onset, and only in the most extreme cases did people report a complete absence of self-experience (Timmermann et al., 2025). Much of what is known about 5-MeO-DMT’s effects comes from surveys and naturalistic settings like this, where nobody checked the substance or the amount. Evidence: preliminary.

How long do the effects last when measured?

Both are short. In the intravenous DMT study, ratings of intensity stayed significantly above placebo for 17 minutes and peaked at 2 to 3 minutes (Timmermann et al., 2019); how long does DMT last covers the other DMT timing studies. Evidence: established.

In the largest 5-MeO-DMT trial, the median duration of psychoactive effect for each administration ranged from 9 to 14 minutes (Cubała et al., 2026). A review gives 10 to 20 minutes as the typical range for 5-MeO-DMT and notes that duration and intensity vary with the study design (Reckweg et al., 2022). Evidence: established. For how these timings compare with psilocybin and LSD, see our classic psychedelics comparison.

What risks have been reported?

In clinical trials, reported harms have been short-lived. A 2024 systematic review found three early-phase 5-MeO-DMT trials with 78 participants in total, no serious adverse events and no dropouts, and called for larger randomized trials with longer follow-up (Kwaśny et al., 2024). Evidence: preliminary.

Outside trials, reviews list fear, anxiety, confusion, paranoia, nausea, vomiting, pressure in the chest, loss of body perception, and brief “reactivations” in the following week, with rare reports of psychosis (Reckweg et al., 2022). Evidence: preliminary.

Population data suggest the experience can be hard on people. A 2026 nationally representative US survey asked about 13 adverse effects that respondents attributed to a substance. Among 72 people who reported 5-MeO-DMT use in the past three months, 92.8% endorsed at least one, compared with 75.6% for psilocybin and 83.6% for LSD. The authors caution that the survey cannot show cause, that the 5-MeO-DMT sample was small, and that its “overwhelming phenomenology” may lead people to blame it for coincidental symptoms (Simonsson et al., 2026). Evidence: preliminary.

What do clinical trials of 5-MeO-DMT show so far?

5-MeO-DMT has moved further into formal drug development than its popularity outside medicine might suggest. The main program is GH001, a synthetic inhaled formulation from GH Research. ClinicalTrials.gov lists eight GH001 studies; trials in postpartum depression and bipolar II disorder were terminated, and none of the sites listed is in Canada (ClinicalTrials.gov). Evidence: established.

The phase 2b trial is the strongest evidence. On the main depression scale, GH001 beat placebo by 15.5 points at day 8. Adverse events affected 72.5% of the GH001 group and 7.3% of the placebo group, mostly nausea, and all were mild or moderate; there were no severe or serious ones in the placebo-controlled week. There was no planned psychotherapy (Cubała et al., 2026). Evidence: preliminary, from one trial.

Its limits matter too. The authors acknowledge that the drug’s effects are hard to hide, which can tell patients and staff who got the real drug (functional unblinding); they used remote, blinded raters to reduce this. The blinded period lasted only a week. In the six-month open-label phase, 20 of the 23 people who had remitted were still in remission, but most had received further treatments (Cubała et al., 2026).

The earlier phase 1/2 study had no control group (Reckweg et al., 2023), and the SSRI study was a small open-label safety study (Seynaeve et al., 2026). The trial authors describe GH001 as a potential treatment, not an established one. Evidence: preliminary. For psilocybin’s depression trials, see psilocybin depression trials.

What is the legal status of 5-MeO-DMT and DMT in Canada?

DMT is controlled. The Controlled Drugs and Substances Act lists N,N-dimethyltryptamine and its salts as item 7 of Schedule III, in the consolidation current to 30 September 2026 (Justice Laws, CDSA). The new Controlled Substances Regulations, which came into force on 1 October 2026, list DMT as a restricted drug in their Schedule 4 (Justice Laws, SOR/2025-242). Evidence: established. See also is DMT legal in Canada.

5-MeO-DMT is not named in either text. We searched both for the substance and its chemical names and found no listing, and the DMT entry covers DMT and its salts, not its derivatives (Justice Laws, CDSA). Evidence: established.

Health Canada’s drug-surveillance site gives 5-MeO-DMT as its example of a “new psychoactive substance”: one not currently controlled under the CDSA, whose sale is regulated under the Food and Drugs Act (Health Canada, Health Infobase; page modified 19 March 2026). A 2022 review also lists Canada among countries where it is not controlled, while noting it has been in US Schedule I since 2009 (Ermakova et al., 2022). Evidence: established.

“Not scheduled” does not mean approved, tested or safe, and the Food and Drugs Act still applies to its sale. Health Canada runs a service that confirms its position on whether a substance not explicitly listed in the CDSA is controlled (Health Canada). We did not find a published determination for 5-MeO-DMT, and the Health Canada page predates the October 2026 regulations. Check the official texts for any later change. This is general information, not legal advice.

What we still don’t know

• Whether 5-MeO-DMT’s 5-HT1A activity explains its reduced visual effects in people, or only in animal and binding studies.
• Whether GH001’s results hold in larger, longer trials with blinding measured, and in patients with more severe or long-standing illness.
• How common serious harms are outside trials. Most case reports are second-hand, and many databases do not test for 5-MeO-DMT.
• How the Sonoran Desert toad makes 5-MeO-DMT, and how its populations are faring since the 2004 assessment.
• Whether the human body produces 5-MeO-DMT at all.

Shroomverse sells mushroom products. This article is general information about the chemistry, natural history, research and legal status of two tryptamines. It is not medical, legal or purchasing advice, and it does not recommend any product.